Accro Bioscience
Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease.
$50MSeries C
Role not disclosedL
LAV
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $227.7M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionSyneron Bio
Develops intelligent platform-driven macrocyclic peptide drug discovery
$150MSeries B
Role not disclosedExcalipoint Therapeutics
Develops next-generation T-cell engager therapies for cancer and autoimmune diseases
$27.7MSeed+
Role not disclosed